ASCO 2023 | MOMENTUM & the potential impact of approval of momelotinib in myelofibrosis
Aaron Gerds
• 5 Jun 2023
Aaron Gerds, MD, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, shares insights into the Phase III MOMENTUM (NCT04173494) trial comparing momelotinib to danazol in anemic patients with symptomatic myelofibrosis (MF) who received prior JAK inhibitor treatment. Whilst FDA approval of this drug is eagerly awaited, it will be important to examine the specific label indications to determine how this drug will be used in clinical practice. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
